Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Bellaire Dermatology

Neither a doctor nor a teaching hospital

Research payments

$687,295

129 payments

Through program year 2025, Bellaire Dermatology is reported as receiving $687,295 in research payments, across 129 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $107,497 12
2024 Research $184,560 5
2023 Research $32,025 10
2022 Research $40,363 7
2021 Research $138,800 40
2020 Research $105,367 33
2019 Research $78,683 22

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $273,553 91 payments
  2. Novartis Pharmaceuticals Corporation $257,424 10 payments
  3. E.R. Squibb & Sons, L.L.C. $112,567 14 payments
  4. Amgen Inc. $17,094 3 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $11,376 2 payments
  6. Regeneron Pharmaceuticals, Inc. $5,834 1 payment
  7. Boehringer Ingelheim Pharma GmbH & Co.KG $4,365 3 payments
  8. Pfizer Inc. $3,500 1 payment
  9. Eli Lilly and Company $1,554 3 payments
  10. Eli Lilly Export S.A. Puerto Rico Branch $27 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Double-Blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-Term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa $174,323 4 payments
  2. M15-997 $77,913 29 payments
  3. 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S $74,999 3 payments
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Non-Segmental Vitiligo $53,163 10 payments
  5. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod $38,185 1 payment
  6. A Phase 3b Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Apremilast for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy $31,161 9 payments
  7. M18-891 $29,084 13 payments
  8. A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence $26,551 8 payments
  9. A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) $25,603 10 payments
  10. Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis $25,446 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record